Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ziritaxestat in Idiopathic Pulmonary Fibrosis: NCT03733444 Clinical Landscape Report 2026
16 October 2026
NCT03733444 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nadofaragene firadenovec-vncg in Malignant Pleural Mesothelioma: NCT03710876 Clinical Landscape Report 2026
16 October 2026
NCT03710876 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nintedanib esylate in Idiopathic Pulmonary Fibrosis: NCT03717012 Clinical Landscape Report 2026
16 October 2026
NCT03717012 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GLPG-1205 in Idiopathic Pulmonary Fibrosis: NCT03725852 Clinical Landscape Report 2026
16 October 2026
NCT03725852 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acetylcysteine in Idiopathic Pulmonary Fibrosis: NCT03720483 Clinical Landscape Report 2026
16 October 2026
NCT03720483 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fitusiran in Hemophilia B: NCT03754790 Clinical Landscape Report 2026
16 October 2026
NCT03754790 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: ACTRN12618001838202 Clinical Landscape Report 2026
16 October 2026
ACTRN12618001838202 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
SPK-8016 in Hemophilia A: NCT03734588 Clinical Landscape Report 2026
16 October 2026
NCT03734588 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nipocalimab-aahu in Myasthenia Gravis: NCT03772587 Clinical Landscape Report 2026
16 October 2026
NCT03772587 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Delandistrogene moxeparvovec in Muscular Dystrophy, Duchenne: NCT03769116 Clinical Landscape Report 2026
16 October 2026
NCT03769116 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: NL-OMON50041 Clinical Landscape Report 2026
16 October 2026
NL-OMON50041 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eculizumab-AAGH in Myasthenia Gravis: NCT03759366 Clinical Landscape Report 2026
16 October 2026
NCT03759366 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.